ArticleInfection and drug resistance2025
Mass Cytometry Analysis of High-Dimensional Single-Cell Immune Profiles in ZF2001-Vaccinated Patients Infected with SARS-CoV-2.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a public health emergency of international concern (PHEIC) by the WHO. ZF2001, a protein subunit vaccine targeting the RBD, was utilized to evaluate its impact on the immune system of COVID-19 patients. This study aimed to investigate peripheral cell profiles one year after three doses of ZF2001 vaccine using single cell mass spectrometry flow cytometry (CyTOF), a technique that allows detailed characterization of the immune response against SARS-COV-2 infection and further evaluation of ZF2001 mechanisms as a prophylactic against chronic disease and reducing mortality. Methods: This study profiled peripheral blood mononuclear cells (PBMCs) from 16 vaccinated COVID-19 patients (Omicron 5.2) and 8 hDs using CyTOF with a 41-antibody panel. PBMCs isolated via Lymphoprep density gradient underwent metal-tagged antibody staining. Data analysis included FlowJo gating, Seurat/Harmony batch correction, PhenoGraph clustering (k=45), and t-SNE visualization. Statistical assessments employed Wilcoxon tests and Spearman correlation. Results: Our findings revealed significant differences between infected and healthy individuals one year after three doses of ZF2001. Specifically, infected individuals exhibited: significant elevation of cytotoxic T cells expressing CD8 with a proliferation marker antigen-Kiel 67 (Ki67) and an adhesion molecule (CD138), expansion of B cells and reduction of monocytes expressing CD16, as well as depletion of CD4+ T cells and differentiation of T cells 1 year after the vaccine. These changes suggested that the vaccine was effectively modulating the immune response. Discussion: Our results provided a detailed single-cell profile of the immune response to SARS-CoV-2 infection in vaccinated patients, highlighting significant changes in immune cell kinetics indicative of an active innate and adaptive immune cell response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.